These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 3488027)

  • 1. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
    Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
    Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].
    Kan N; Inamoto T; Hori T; Nio Y; Tsuchitani T; Kodama H; Tobe T; Ohgaki K
    Nihon Gan Chiryo Gakkai Shi; 1985 May; 20(4):784-96. PubMed ID: 3877129
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.
    Kan N; Okino T; Nakanishi M; Sato K; Mise K; Yamasaki S; Teramura Y; Ohgaki K; Tobe T
    Biotherapy; 1989; 1(3):197-206. PubMed ID: 2642023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
    Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
    Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
    Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
    Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
    Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of heat treatment on tumor cells and antitumor effector cells.
    Mise K; Kan N; Okino T; Nakanishi M; Satoh K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
    Cancer Res; 1990 Oct; 50(19):6199-202. PubMed ID: 2400985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of gastric cancer].
    Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice.
    Saito M; Nanjo M; Kataoka M; Moriya Y; Sugawara Y; Yoshida T; Ishida N
    Cancer Res; 1988 Aug; 48(15):4163-7. PubMed ID: 3390809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
    Hashimoto M; Takashige K; Furuyashiki M; Yoshidome K; Sano R; Kawamura Y; Ijichi S; Morioka H; Koide H; Oku N; Moriya Y; Kusumoto S; Suda Y
    Int Immunopharmacol; 2008 Jan; 8(1):12-9. PubMed ID: 18068095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of OK-432 on the lymphnode metastasis of MCA-sarcoma cell lines: a new therapeutic approach.
    Inoh A; Kodama Y; Yokoro K
    Hiroshima J Med Sci; 1989 Dec; 38(4):213-9. PubMed ID: 2637250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R; Kamdar SJ; Duffy T; Edison L
    J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
    Ujiie T
    Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation by OK-432 of generation of culture-induced killer cells.
    Ujiie T
    Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
    Hihara J; Yamaguchi Y; Minami K; Noma K; Toge T
    Anticancer Res; 1999; 19(2A):1077-84. PubMed ID: 10368657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.